OR WAIT 15 SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
February 18, 2021
The deal expands Wavelength’s drug substance manufacturing footprint and its API CDMO business.
February 16, 2021
The increased services will work in conjunction with the site’s SimpliFiH Solutions first-in-human services, which includes phase-appropriate drug substance and drug product development and manufacturing.
February 03, 2021
Advanced manufacturing technologies are available, but challenges need to be addressed.
December 03, 2020
Operator, caregiver, and patient safety are at the forefront when selecting the best options and dosage forms.
November 18, 2020
The expansion will be designed to meet the growing demand for small molecule drug substance development and manufacturing.
November 03, 2020
Biological and analytical advances enable modern fermentation processes to deliver safe and effective next-generation medicines.
September 21, 2020
Roche will gain full rights to Inflazome’s portfolio which includes clinical and preclinical orally available small molecule NLRP3 inhibitors.
September 03, 2020
Risk-based decision-making is impacting all aspects of manufacturing quality from raw material supply to facility inspections.
September 02, 2020
For certain APIs, including semi-synthetic antibiotics, continuous filtration and drying improves productivity and quality.
August 20, 2020
CARBOGEN AMCIS has announced significant investments to increase manufacturing capacity in Switzerland and France.
August 13, 2020
Atomwise’s technology, AtomNet, works to eliminate the barriers of physical screening for small molecule drug discovery.
July 08, 2020
CordenPharma added a 3000-L solid-phase peptide synthesis vessel to its GMP API facility in Boulder, CO.
May 19, 2020
HHS announces $354 million in funding for private industry to manufacture generic drugs in the US from raw materials to finished product.
May 06, 2020
Quartic.ai and Bright Path Laboratories have agreed to develop an artificial intelligence (AI)-powered continuous manufacturing platform for APIs and other small-molecule drugs using Bright Path Labs’ continuous bioreactor and the Quartic.ai smart manufacturing technology.
May 02, 2020
Many antibody-drug conjugate therapies are in the pipeline; however, only a handful have been approved. What are the bottlenecks?
Discovery of carcinogenic nitrosamines in three of the world’s most widely prescribed drugs is driving efforts to better detect, control and prevent their generation in APIs and finished drug products.
April 23, 2020
Wavelength Pharmaceuticals expanded production of APIs for certain pharmaceutical products needed to manage respiratory critical care patients in the COVID-19 pandemic.
April 16, 2020
The technology center is dedicated to developing greener, safer chemistries for manufacturing pharmaceutical raw materials and intermediates.
March 25, 2020
Bayer, Novartis, Mylan, Teva, report that they are working on supply.
March 02, 2020
Formulating fixed-dose combination drugs proves more complex than simply adding one ingredient to another.